Literature DB >> 2776110

The prognostic value of histologic subtypes in primary extremity liposarcoma.

H R Chang1, S I Hajdu, C Collin, M F Brennan.   

Abstract

Patients with a localized primary liposarcoma of the extremity who were treated in Memorial Sloan-Kettering Cancer Center between 1968 and 1978 were studied. The prognosis of patients with extremity liposarcoma was analyzed according to histopathologic subtypes. A system of five subtypes was used; well-differentiated, myxoid, fibroblastic, lipoblastic, and pleomorphic liposarcomas. The 5-year treatment failure rates and survival rates were, respectively, 30% and 100% for well-differentiated, 25% and 88% for myxoid, 60% and 58% for fibroblastic, 100% and 40% for lipoblastic, and 64% and 56% for pleomorphic liposarcomas. Although local recurrence was present in all five subtypes, a significant increment in local failure was seen in patients with high-grade liposarcomas. Distant metastasis after the initial operation was not found in patients with well-differentiated liposarcoma and rare in the patients with myxoid liposarcoma. In contrast, 50% of the patients with fibroblastic, lipoblastic, and pleomorphic liposarcoma had a distant relapse within 5 years.

Entities:  

Mesh:

Year:  1989        PMID: 2776110     DOI: 10.1002/1097-0142(19891001)64:7<1514::aid-cncr2820640726>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Multifactorial analysis of survival in primary extremity liposarcoma.

Authors:  H R Chang; J Gaynor; C Tan; S I Hajdu; M F Brennan
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Risk assessment in liposarcoma patients based on FDG PET imaging.

Authors:  Winfried Brenner; Janet F Eary; Willy Hwang; Cheryl Vernon; Ernest U Conrad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

3.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Liposarcoma: a soft tissue tumor with many presentations.

Authors:  H J Mankin; K P Mankin; D C Harmon
Journal:  Musculoskelet Surg       Date:  2014-07-22

5.  Retroperitoneal and scrotal giant liposarcoma: report of a case.

Authors:  S Yol; S Tavli; L Tavli; M Belviranli; A Yosunkaya
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

6.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

Authors:  P Tontonoz; S Singer; B M Forman; P Sarraf; J A Fletcher; C D Fletcher; R P Brun; E Mueller; S Altiok; H Oppenheim; R M Evans; B M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

7.  Primary liposarcoma of the heart.

Authors:  Christina Maria Steger
Journal:  BMJ Case Rep       Date:  2011-05-03

8.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

9.  Metastatic myxoid liposarcomas: imaging and histopathologic findings.

Authors:  Kenneth Sheah; Hugue A Ouellette; Martin Torriani; G Petur Nielsen; Susan Kattapuram; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2007-12-21       Impact factor: 2.199

10.  Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma.

Authors:  Rosalvo Zósimo Bispo Júnior; Olavo Pires de Camargo; Cláudia Regina G C M de Oliveira; Renée Zon Filippi; André Mathias Baptista; Marcelo Tadeu Caiero
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.